Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference.

Mainwaring P, Akaza H.

Prostate Int. 2015 Dec;3(Suppl):S1-4. doi: 10.1016/j.prnil.2015.10.014. Epub 2015 Oct 22. No abstract available.

PMID:
26858943
2.

Sequence of treatment in locally advanced and metastatic renal cell carcinoma.

Fischer S, Gillessen S, Rothermundt C.

Transl Androl Urol. 2015 Jun;4(3):310-25. doi: 10.3978/j.issn.2223-4683.2015.04.07. Review.

3.

Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.

Vue B, Zhang S, Zhang X, Parisis K, Zhang Q, Zheng S, Wang G, Chen QH.

Eur J Med Chem. 2016 Feb 15;109:36-46. doi: 10.1016/j.ejmech.2015.12.041. Epub 2015 Dec 24.

PMID:
26748997
4.

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer.

Mang J, Korzeniewski N, Dietrich D, Sailer V, Tolstov Y, Searcy S, von Hardenberg J, Perner S, Kristiansen G, Marx A, Roth W, Herpel E, Grüllich C, Popeneciu V, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.

Transl Oncol. 2015 Dec;8(6):487-96. doi: 10.1016/j.tranon.2015.11.004.

5.

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.

Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A.

J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015.

6.

STAMP2 increases oxidative stress and is critical for prostate cancer.

Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F.

EMBO Mol Med. 2015 Feb 13;7(3):315-31. doi: 10.15252/emmm.201404181.

7.

A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.

Zhou T, Zeng SX, Ye DW, Wei Q, Zhang X, Huang YR, Ye ZQ, Yang Y, Zhang W, Tian Y, Zhou FJ, Jie J, Chen SP, Sun Y, Xie LP, Yao X, Na YQ, Sun YH.

PLoS One. 2015 Jan 27;10(1):e0117002. doi: 10.1371/journal.pone.0117002. eCollection 2015.

8.

Androgen receptors beyond prostate cancer: an old marker as a new target.

Munoz J, Wheler JJ, Kurzrock R.

Oncotarget. 2015 Jan 20;6(2):592-603. Review.

9.

Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.

Hoang DT, Gu L, Liao Z, Shen F, Talati PG, Koptyra M, Tan SH, Ellsworth E, Gupta S, Montie H, Dagvadorj A, Savolainen S, Leiby B, Mirtti T, Merry DE, Nevalainen MT.

Mol Cancer Ther. 2015 Mar;14(3):713-26. doi: 10.1158/1535-7163.MCT-14-0819. Epub 2014 Dec 31.

PMID:
25552366
10.

Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation.

Mardilovich K, Gabrielsen M, McGarry L, Orange C, Patel R, Shanks E, Edwards J, Olson MF.

Mol Cancer Ther. 2015 Jan;14(1):246-58. doi: 10.1158/1535-7163.MCT-14-0447. Epub 2014 Oct 24.

11.
12.

Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells.

Mathur A, Abd Elmageed ZY, Liu X, Kostochka ML, Zhang H, Abdel-Mageed AB, Mondal D.

PLoS One. 2014 Aug 14;9(8):e103109. doi: 10.1371/journal.pone.0103109. eCollection 2014.

13.

Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.

Zhao X, Huang S, Luo H, Wan X, Gui Y, Li J, Wu D.

Int J Clin Exp Med. 2014 May 15;7(5):1204-13. eCollection 2014.

14.

Reappraisal of glucocorticoids in castrate-resistant prostate cancer.

Sartor O, Parker CC, de Bono J.

Asian J Androl. 2014 Sep-Oct;16(5):666. doi: 10.4103/1008-682X.133314.

15.

The developing story of Sprouty and cancer.

Masoumi-Moghaddam S, Amini A, Morris DL.

Cancer Metastasis Rev. 2014 Sep;33(2-3):695-720. doi: 10.1007/s10555-014-9497-1. Review.

16.

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.

Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE.

EMBO Mol Med. 2014 May 1;6(5):651-61. doi: 10.1002/emmm.201303581.

17.

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT.

Mol Cancer Ther. 2014 May;13(5):1246-58. doi: 10.1158/1535-7163.MCT-13-0605. Epub 2014 Feb 27.

18.

Molecular imaging of urogenital diseases.

Cho SY, Szabo Z.

Semin Nucl Med. 2014 Mar;44(2):93-109. doi: 10.1053/j.semnuclmed.2013.10.008. Review.

19.

The stroma-a key regulator in prostate function and malignancy.

Hägglöf C, Bergh A.

Cancers (Basel). 2012 May 29;4(2):531-48. doi: 10.3390/cancers4020531.

20.

Targeted α-particle therapy of bone metastases in prostate cancer.

Jadvar H, Quinn DI.

Clin Nucl Med. 2013 Dec;38(12):966-71. doi: 10.1097/RLU.0000000000000290. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk